Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 3, 2014, Pages 597-602

  Wang, Yichen ^a   Yang, Huayu ^a   Xu, Haifeng ^a   Lu, Xin ^a   Sang, Xinting ^a   Zhong, Shouxian ^a   Huang, Jiefu ^a   Mao, Yilei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Differential diagnosis; Glypican 3; Golgi protein 73; Hepatocellular carcinoma; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; CELL PROTEIN; GLYPICAN 3; GOLGI PROTEIN 73; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; VIRUS CARRIER;

DIFFERENTIAL DIAGNOSIS; GLYPICAN-3; GOLGI PROTEIN 73; HEPATOCELLULAR CARCINOMA; Α-FETOPROTEIN;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84897623755     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12461     Document Type: Article

References (27)

1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
2. Matsuda K. Novel susceptibility loci for hepatocellular carcinoma in chronic HBV carriers. Hepatobiliary Surg. Nutr. 2012; 1: 59-60.
3. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2009; 138: 493-502.
4. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
5. Trevisani F, D'Intino PE, Morselli-Labate AM etal. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001; 34: 570-575.
6. Mao Y, Yang H, Xu H etal. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59: 1687-1693.
7. Block TM, Comunale MA, Lowman M etal. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 779-784.
8. Marrero JA, Romano PR, Nikolaeva O etal. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol. 2005; 43: 1007-1012.
9. Witjes CD, van Aalten SM, Steyerberg EW etal. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol. Int. 2013; 7: 59-64.
10. Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer 2012; 12: 17.
11. Filmus J, Shi W, Wong ZM, Wong MJ. Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem. J. 1995; 311: 561-565.
12. Saunders S, Paine-Saunders S, Lander AD. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev. Biol. 1997; 190: 78-93.
13. Pilia G, Hughes-Benzie RM, MacKenzie A etal. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet. 1996; 12: 241-247.
14. Capurro M, Wanless IR, Sherman M etal. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
15. Ozkan H, Erdal H, Kocak E etal. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J. Clin. Lab. Anal. 2011; 25: 350-353.
16. Yasuda E, Kumada T, Toyoda H etal. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol. Res. 2010; 40: 477-485.
17. Chen M, Li G, Yan J etal. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin. Chim. Acta 2013; 423: 105-111.
18. Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma. Am. J. Gastroenterol. 2004; 99: 1096-1098.
19. Mao YL, Yang HY, Xu HF etal. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi 2008; 88: 948-951.
20. Kladney RD, Tollefson AE, Wold WS, Fimmel CJ. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology 2002; 301: 236-246.
21. Yano Y, Seo Y, Azuma T, Hayashi Y. Hepatitis B virus and host factors. Hepatobiliary Surg. Nutr. 2013; 2: 121-123.
22. Yao M, Yao DF, Bian YZ etal. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2013; 12: 171-179.
23. Jakubovic BD, Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp. Mol. Pathol. 2007; 82: 184-189.
24. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57: 5179-5184.
25. Tangkijvanich P, Chanmee T, Komtong S etal. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J. Gastroenterol. Hepatol. 2009; 25: 129-137.
26. Gonzalez AD, Kaya M, Shi W etal. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J. Cell Biol. 1998; 141: 1407-1414.
27. Murthy SS, Shen T, De Rienzo A etal. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000; 19: 410-416.